96 related articles for article (PubMed ID: 27885372)
1. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
2. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
3. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
[TBL] [Abstract][Full Text] [Related]
4. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
[TBL] [Abstract][Full Text] [Related]
5. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
Hardiansyah D; Riana A; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
[TBL] [Abstract][Full Text] [Related]
6. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
9. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy.
Rinscheid A; Lee J; Kletting P; Beer AJ; Glatting G
Z Med Phys; 2019 Dec; 29(4):314-325. PubMed ID: 30611606
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
[TBL] [Abstract][Full Text] [Related]
11. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
13. (90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
Fabbri C; Bartolomei M; Mattone V; Casi M; De Lauro F; Bartolini N; Gentili G; Amadori S; Agostini M; Sarti G
Cancer Biother Radiopharm; 2015 Jun; 30(5):200-10. PubMed ID: 25860616
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
15. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy.
Maaß C; Kletting P; Bunjes D; Mahren B; Beer AJ; Glatting G
Cancer Biother Radiopharm; 2015 Sep; 30(7):285-90. PubMed ID: 26172337
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
[TBL] [Abstract][Full Text] [Related]
18. The NUKDOS software for treatment planning in molecular radiotherapy.
Kletting P; Schimmel S; Hänscheid H; Luster M; Fernández M; Nosske D; Lassmann M; Glatting G
Z Med Phys; 2015 Sep; 25(3):264-74. PubMed ID: 25791740
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
[TBL] [Abstract][Full Text] [Related]
20. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of
Siebinga H; de Wit-van der Veen BJ; Beijnen JH; Stokkel MPM; Dorlo TPC; Huitema ADR; Hendrikx JJMA
EJNMMI Res; 2021 Aug; 11(1):73. PubMed ID: 34398356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
